Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
08/2000
08/17/2000WO2000047718A1 Isolation of stem cells and methods of use thereof
08/17/2000WO2000047622A2 Peptides with anti-angiogenic activity
08/17/2000WO2000047619A1 Therapeutics and diagnostics based on an il-1b mutation
08/17/2000WO2000047615A2 Proteins related to neuronal regeneration and uses thereof
08/17/2000WO2000047602A1 33 human secreted proteins
08/17/2000WO2000047599A1 Novel nucleosides and oligonucleotide analogues
08/17/2000WO2000047237A1 Encapsulated cells containing an amplified expression vector as a drug delivery device
08/17/2000WO2000047235A2 Methods of stimulating angiogenesis
08/17/2000WO2000047231A2 Novel antisense inhibition of rad51
08/17/2000WO2000047229A2 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
08/17/2000WO2000047223A2 Viral vaccine
08/17/2000WO2000047217A2 Protection of cells in connection with treatment with chemical agents
08/17/2000WO2000047186A1 Polynucleotide compositions for intramuscular and intradermal administration
08/17/2000WO2000047104A2 Antagonists of hmg1 for treating inflammatory conditions
08/17/2000WO2000030590A3 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
08/17/2000WO2000024766A3 New transcription factor of mhc class ii genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
08/17/2000WO2000018912A3 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases
08/17/2000WO2000015784A3 Human and murine g-protein-coupled edg6 receptor (endothelial differentiation gene) and use of same
08/17/2000WO2000014262A9 Methylation of plasmid vectors
08/17/2000WO2000014230A9 Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
08/17/2000WO2000005393A3 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
08/17/2000DE19956568A1 Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens Method and medicament for the inhibition of expression of a given gene
08/17/2000DE19906108A1 Schutz von Zellen im Zusammenhang mit einer Behandlung mit chemischen Agenzien Protecting cells in connection with a treatment with chemical agents
08/17/2000DE19905501A1 Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels A method of producing a recombinant adeno-associated virus, as well as suitable means to this end use for the preparation of a medicament
08/17/2000DE19904650A1 cDNA-Sequenz eines Interaktors FANCIP1 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequence of an interactor FANCIP1 of the Fanconi anemia complementation group A protein
08/17/2000CA2366487A1 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
08/17/2000CA2362523A1 Nitroreductase enzymes
08/17/2000CA2362295A1 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
08/17/2000CA2362109A1 Novel antisense inhibition of rad51
08/17/2000CA2361335A1 Inhibiting formation of atherosclerotic lesions
08/17/2000CA2361293A1 33 human secreted proteins
08/17/2000CA2361034A1 Proteins related to neuronal regeneration and uses thereof
08/17/2000CA2360123A1 Encapsulated cells containing an amplified expression vector as a drug delivery device
08/17/2000CA2360103A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
08/17/2000CA2359926A1 Antagonists of hmg1 for treating inflammatory conditions
08/17/2000CA2359886A1 Polynucleotide compositions for intramuscular and intradermal administration
08/17/2000CA2359748A1 Method of producing a recombinant adeno-associated virus, suitable means for producing the same and use thereof for producing a medicament
08/16/2000EP1027834A1 Food composition comprising L-arginine
08/16/2000EP1027443A2 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
08/16/2000EP1027440A1 Inhibitor protein of the wnt signal pathway
08/16/2000EP1027438A2 Novel cytokine receptors
08/16/2000EP1027435A2 Nucleic acid molecule encoding a (poly)peptide co-segregating in mutated form with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (apeced)
08/16/2000EP1027431A2 April- a novel protein with growth effects
08/16/2000EP1027429A1 Jnk3 modulators and methods of use
08/16/2000EP1027076A2 Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
08/16/2000EP1027075A1 Gene therapy for stimulation of angiogenesis
08/16/2000EP1027074A1 Compositions and methods for delivery of genetic material
08/16/2000EP1027069A1 Compositions and methods for treating lysosomal storage disease
08/16/2000EP1027033A2 High efficiency encapsulation of charged therapeutic agents in lipid vesicles
08/16/2000EP1027014A1 Implantable system with drug-eluting cells for on-demand local drug delivery
08/16/2000EP0644929B1 System and method for transplantation of cells
08/16/2000CN1263560A Methods for diagnosis and treating cancers, and methods for identifying pathogenic markers in sample of normal cells
08/16/2000CN1263556A Anti-GPIIB/IIIA recombinant antibodies
08/16/2000CN1263473A Composition and method for enhancing transport across biological membranes
08/16/2000CN1263159A New type simple herpesvirus amplicon carrier system and its application
08/15/2000US6103890 Enzymatic nucleic acids that cleave C-fos
08/15/2000US6103877 Purified antibody which specifically binds to human hypermethylated in cancer-1 polypeptide of specific amino acid sequence or its immunoreactive fragments; for diagnosis/ prognosis of cell proliferative disorders such as cancer
08/15/2000US6103874 Human KDEL receptor
08/15/2000US6103873 Isolated renal cancer specific antigen
08/15/2000US6103710 Glucocorticoid response elements
08/15/2000US6103531 Decreasing levels of janus kinase i by introducing isolated gene product of cytomegalovirus early gene, immediate early gene or mixture into cell
08/15/2000US6103530 Medium for proliferating central nervous system stem cells includes standard basal medium; a carbohydrate; insulin, transferrin, progesterone, selenium, and/or putrescine; cell growth factors; and leukemia inhibitory factor
08/15/2000US6103527 Nucleotide sequence from gene expressed in proliferating endothelial cells; for controlled gene expression especially for transgenic tissues and gene therapy
08/15/2000US6103513 Novel proteolytic enzyme; for the treatment of immune, proliferative and degratory defects
08/15/2000US6103507 Protein used to raise an immunological response against a bacteria; bactericides
08/15/2000US6103494 Nucleotide sequences which code protein associated with immmune response; for the detection of flea allergy dermatitis; for the detection of modulators of immune response
08/15/2000US6103470 Plasmid for delivery of nucleic acids to cells and methods of use
08/15/2000US6103466 Obtaining dna sample from mammal and determining if nucleotide sequence encodes a biologically active protein of myostatin; amplifying dna with primers flanking natural mutation which when present in both alleles results in muscular hyperplasia
08/15/2000US6103230 Methods for promoting wound healing and treating transplant-associated vasculopathy
08/15/2000US6103226 Co-transfecting the cell with one or more expression vectors containing polynucleotides that encode tyrosine hydroxylase, aromatic l-amino acid decarboxylase and gtp cyclohydrolase.
08/15/2000CA2202280C Sugar modified nucleosides and their use for synthesis of oligonucleotides
08/10/2000WO2000046391A2 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof
08/10/2000WO2000046386A2 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
08/10/2000WO2000046385A1 Gene repair involving in vivo excision of targeting dna
08/10/2000WO2000046384A1 Nucleic acid uptake and release vehicle
08/10/2000WO2000046377A1 Genetically engineered retroviral vector particles capable of infecting non-dividing cells
08/10/2000WO2000046365A1 Advanced antigen presentation platform
08/10/2000WO2000046360A1 Improved helper dependent vector system for gene therapy
08/10/2000WO2000046347A1 Genetic and epigenetic regulation of abc transporters and ect0-phosphatases for the modulation of drug resistance
08/10/2000WO2000046344A2 Non-stochastic generation of genetic vaccines and enzymes
08/10/2000WO2000046247A1 Methods of use for dna molecules encoding m68, a tnf receptor-related protein
08/10/2000WO2000046246A1 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
08/10/2000WO2000046244A1 cDNA SEQUENCE OF AN INTERACTOR FANCIP1 OF THE FANCONI ANAEMIA PROTEIN OF COMPLEMENTATION GROUP A
08/10/2000WO2000046240A2 Polypeptides involved in immune response
08/10/2000WO2000045853A2 Treatment of tumors with genetically engineered herpes virus
08/10/2000WO2000045852A1 Method of treating cancer by restoration of pp32 function
08/10/2000WO2000045851A2 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
08/10/2000WO2000045849A2 Use of cationic lipids to generate anti-tumor immunity
08/10/2000WO2000045840A1 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence
08/10/2000WO2000045835A1 Vascular endothelial growth factor-2
08/10/2000WO2000045825A1 Delivery system and methods for gene therapy
08/10/2000WO2000045792A1 Hydrogel particle formulations
08/10/2000WO2000045791A2 Method for controlling liposome size
08/10/2000WO2000025827A3 Dna molecules encoding muc-1 and use thereof in tumor vaccination
08/10/2000WO2000024359A3 Use of gndf for treating retinal degeneration
08/10/2000WO2000013706A8 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
08/10/2000WO2000012118A8 Inhibiting cardiomyocyte death
08/10/2000WO2000010588A9 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
08/10/2000WO1999066072A3 Methods for treating a neurological disease by determining bche genotype
08/10/2000WO1999006547A3 Products of gene and protein therapy of cystic fibrosis and inducers of a glutathiones-s-transferase
1 ... 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 ... 870